← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT07590752

NCT07590752 "Dexa vs Dexmedetomidine With Bupivacaine in TAP Block for Laparotomy Analgesia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07590752
Status Recruiting
Phase Phase 2, Phase 3
Sponsor Sahiwal medical college sahiwal
Condition Pain, Postoperative
Study Type INTERVENTIONAL
Enrollment 96 participants
Start Date 2024-03-03
Primary Completion 2026-06-03

Eligibility & Interventions

Sex All sexes
Min Age 25 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Bupivacaine Hcl 0.25% Inj_#1Bupivacaine Hcl 0.25% Inj_#2

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 96 participants in total. It began in 2024-03-03 with a primary completion date of 2026-06-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Transversus abdominis plane block is a regional anesthetic technique which blocks the abdominal neural afferents by introducing local anesthetic into the neuro-fascial plane between the internal oblique and the transversus abdominis muscle and gives analgesia from the skin to parietal peritoneum. There are studies showing evidence of improved post operative analgesia with addition of adjuvants such as dexmedetomidine or dexamethasone in comparison with plane local anesthesia in terms of time to rescue analgesia and the overall quantity of analgesic used post operatively.

Eligibility Criteria

Inclusion Criteria: * Patients undergoing laparotomy. * Patients aged 25 to 65 years. * Both genders. * Patients with ASA Class I, II. Exclusion Criteria: * Patients who do not give consent. * Patients with Comorbidities like DM, HTN, CKD, CLD. * Patients with bleeding disorders. * Infection at site of injection. * Allergy to any drug, local anaesthetic, or other drugs used. * Patients with polytrauma.

Contact & Investigator

Central Contact

Dr Maryam Mumtaz, MBBS

✉ Maryamsumra3@gmail.com

📞 00923336238201

Principal Investigator

Adeel Riaz, MD

STUDY DIRECTOR

Sahiwal medical college sahiwal

Frequently Asked Questions

Who can join the NCT07590752 clinical trial?

This trial is open to participants of all sexes, aged 25 Years or older, up to 65 Years, studying Pain, Postoperative. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07590752 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT07590752 currently recruiting?

Yes, NCT07590752 is actively recruiting participants. Contact the research team at Maryamsumra3@gmail.com for enrollment information.

Where is the NCT07590752 trial being conducted?

This trial is being conducted at Sahiwal, Pakistan.

Who is sponsoring the NCT07590752 clinical trial?

NCT07590752 is sponsored by Sahiwal medical college sahiwal. The principal investigator is Adeel Riaz, MD at Sahiwal medical college sahiwal. The trial plans to enroll 96 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology